[go: up one dir, main page]

RU94040856A - Вакцина для перорального введения - Google Patents

Вакцина для перорального введения

Info

Publication number
RU94040856A
RU94040856A RU94040856/14A RU94040856A RU94040856A RU 94040856 A RU94040856 A RU 94040856A RU 94040856/14 A RU94040856/14 A RU 94040856/14A RU 94040856 A RU94040856 A RU 94040856A RU 94040856 A RU94040856 A RU 94040856A
Authority
RU
Russia
Prior art keywords
vaccine
antigens
oral administration
oral
lipid
Prior art date
Application number
RU94040856/14A
Other languages
English (en)
Inventor
Тсутия Сейси
Jp]
Арамаки Юкихико
Хара Тосифуми
Кикути Хироси
Яти Кието
Икеути Тохру
Original Assignee
Дайити Фармасьютикал Ко.
Дайити Фармасьютикал Ко., Лтд.
Лтд. (Jp)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайити Фармасьютикал Ко., Дайити Фармасьютикал Ко., Лтд., Лтд. (Jp) filed Critical Дайити Фармасьютикал Ко.
Publication of RU94040856A publication Critical patent/RU94040856A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение касается вакцины для перорального введения, содержащей комплекс антигенов и липида, причем липид представляет собой гликолипид, имеющий остаток маннозы, и/или фосфолипид, являющийся фосфатидилсерином. Эта пероральная вакцина способна эффективно продуцировать антитела к содержащимся в ней антигенам после перорального введения ее в живые организмы. Следовательно, теперь можно получать пероральную вакцину, содержащую микробные антигены или ослабленные микроорганизмы, которые не могли абсорбироваться при пероральном введении вакцины и которые не могли продуцировать антитела к антигенам в предыдущей практике.

Claims (1)

  1. Изобретение касается вакцины для перорального введения, содержащей комплекс антигенов и липида, причем липид представляет собой гликолипид, имеющий остаток маннозы, и/или фосфолипид, являющийся фосфатидилсерином. Эта пероральная вакцина способна эффективно продуцировать антитела к содержащимся в ней антигенам после перорального введения ее в живые организмы. Следовательно, теперь можно получать пероральную вакцину, содержащую микробные антигены или ослабленные микроорганизмы, которые не могли абсорбироваться при пероральном введении вакцины и которые не могли продуцировать антитела к антигенам в предыдущей практике.
RU94040856/14A 1992-03-03 1993-03-02 Вакцина для перорального введения RU94040856A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP45528/1992 1992-03-03
JP4552892 1992-03-03

Publications (1)

Publication Number Publication Date
RU94040856A true RU94040856A (ru) 1996-08-20

Family

ID=12721912

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94040856/14A RU94040856A (ru) 1992-03-03 1993-03-02 Вакцина для перорального введения

Country Status (6)

Country Link
EP (1) EP0640347A1 (ru)
KR (1) KR950700083A (ru)
CA (1) CA2131442A1 (ru)
FI (1) FI944052A0 (ru)
RU (1) RU94040856A (ru)
WO (1) WO1993017702A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728476B1 (en) * 1992-04-10 2002-09-04 Hisamitsu Pharmaceutical Co., Inc. Liposome composition
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6656481B1 (en) 1996-09-06 2003-12-02 Mitsubishi Chemical Corporation Vaccinal preparations
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6669679B1 (en) 2000-01-07 2003-12-30 Acist Medical Systems, Inc. Anti-recoil catheter
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
GB0426481D0 (en) 2004-12-02 2005-01-05 Vaccine Technology Ltd Composition
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
WO2009043165A1 (en) * 2007-10-03 2009-04-09 Immunovaccine Technologies Inc. Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
WO2011105520A1 (ja) 2010-02-26 2011-09-01 国立大学法人 長崎大学 抗原または薬物送達複合体
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
WO2013137854A1 (en) * 2012-03-12 2013-09-19 Empire Technology Development Llc Antibodies that bind to nanoparticles
FR3119325B1 (fr) * 2021-01-29 2023-08-11 Renault Jean Yves Compositions liposomales orales

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564500A (en) * 1975-09-29 1980-04-10 Wellcome Found Biological preparations
US4199565A (en) * 1979-03-26 1980-04-22 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
CA1256372A (en) * 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
FR2596651B1 (fr) * 1986-04-08 1989-11-10 Centre Nat Rech Scient Nouveaux liposomes a base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant
JPS63107742A (ja) * 1986-05-20 1988-05-12 Wako Pure Chem Ind Ltd 新規な機能性リポソ−ム及びその製造法
JP2641472B2 (ja) * 1988-01-30 1997-08-13 日本レダリー株式会社 感染症治療剤
US5169636A (en) * 1988-03-17 1992-12-08 Nippon Fine Chemical Co., Ltd. Liposomes

Also Published As

Publication number Publication date
FI944052L (fi) 1994-09-02
FI944052A7 (fi) 1994-09-02
FI944052A0 (fi) 1994-09-02
KR950700083A (ko) 1995-01-16
WO1993017702A1 (fr) 1993-09-16
CA2131442A1 (en) 1993-09-04
EP0640347A1 (en) 1995-03-01

Similar Documents

Publication Publication Date Title
RU94040856A (ru) Вакцина для перорального введения
RU95112465A (ru) Пирановые соединения, фармацевтическая композиция, способ получения и промежуточные соединения
RU95106362A (ru) Производные липопептида, способ их получения, содержащая их фармацевтическая композиция и способ ее получения
FI922151A0 (fi) Metall-peptidkompositioner och metoder foer stimulering av haortillvaext.
NO308126B1 (no) Fosfolipidbasert forbindelse, anvendelse derav samt røntgenkontrastmiddel
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
AU7619291A (en) Use of baclofen for obtaining medicaments for the treatment of angina pectoris
DK0783297T3 (da) Polyethylenglycol-modificerede ceramid-lipider og liposomer
RU94042393A (ru) Галихондрины, родственные соединения и способ лечения опухоли у млекопитающих
DK0859632T3 (da) Influenzavaccinepræparater
SE8404707L (sv) Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav
AU2316892A (en) Multiple emulsions and methods of preparation
RU94024566A (ru) Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики
GR3029774T3 (en) Method of preparing a radioactive rhenium complex solution.
FI972384A0 (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-terminaalisia sulfonyyli- tai amidinosulfonyyliryhmiä
ATE94757T1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen.
EP0642507A4 (en) Catalytic antibodies against cocaine and methods of using and producing same.
EP0954529A4 (en) Porphyromonas gingivalis antigen for the diagnosis and treatment of periodontitis
AU8240387A (en) Basically substituted phenylacetonitriles, their preparation and drugs containing these compounds
DK0563256T3 (da) Anvendelse af værtscelle-phospholipider til inhibering af bakteriekolonisering
ES2056378T3 (es) Procedimiento de extraccion.
AU5852580A (en) 3,4,5-trihydroxypiperidine compounds
Matthews-Greer et al. Pseudomonas aeruginosa outer membrane protein F produced in Escherichia coli retains vaccine efficacy
SE8702734L (sv) Monoklonala antikroppar mot pseudomonas aeruginosa-flageller
ES2170377T3 (es) Composicion que contiene quitosana.